Studies show that ACTOS has positive effects on dyslipidemia, insulin resistance.

Publication: Health & Medicine Week

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2004 NewsRX

2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Two clinical studies presented at the American Diabetes Association's (ADA) Scientific Sessions showed that ACTOS (pioglitazone HCl) has favorable effects on dyslipidemia and insulin resistance.

Dyslipidemia and insulin resistance are two key components of the metabolic syndrome, which is often exhibited in patients with type 2 diabetes.

"When you put the pieces together, these separate findings are very exciting because they show that ACTOS therapy can provide benefits extending beyond improvements in glucose levels," said Mehmood Khan, MD, FACE, senior vice president for medical and...

Read the full article for free courtesy of your local library.